Bayer receives China approval for asundexian. Bayer stock gains 3.18 percent

Published on 10/26/2026 at 15:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

China approved Bayer's Sunharbo as the first Factor XIa drug worldwide. Bayer stock costs EUR 45.38 on October 26, 2026, 3.18 percent above Xetra close.

Bayer adds a China pipeline milestone

Bayer received Chinese marketing authorization for asundexian under the Sunharbo brand on October 26, 2026.
The Factor XIa inhibitor is the first of its class approved worldwide, based on the 12,327-participant OCEANIC-STROKE study.
Bayer stock was trading at EUR 45.38 at Lang & Schwarz on October 26, 2026, 3.18 percent above the Xetra close of EUR 43.98.

Bayer, DE000BAY0017, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) received Chinese marketing authorization for asundexian while its stock was trading at EUR 45.38 at Lang & Schwarz on October 26, 2026, 3.18 percent above the Xetra close of EUR 43.98. According to Bayer on October 26, 2026, China's National Medical Products Administration approved the 50 mg drug under the brand name Sunharbo.

China creates a commercial foothold

The approval gives Bayer's Pharmaceuticals division its first worldwide authorization for a Factor XIa inhibitor. The indication covers stroke-risk reduction in adults after a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

Bayer said the decision was based on the global Phase III OCEANIC-STROKE study. The trial randomized 12,327 participants and compared asundexian combined with antiplatelet therapy against antiplatelet therapy alone. The company reported superiority in reducing ischemic stroke, while the incidence of all bleeding events was similar between the groups.

What the 3.18 percent move prices in

The market reaction adds a measurable signal to the regulatory milestone, but the approval does not yet provide a sales forecast. Bayer said additional marketing applications remain under review in other markets, so China is the first commercial authorization rather than a global launch.

The distinction matters for Bayer stock because the new product offers pipeline progress while the financial contribution still depends on launch timing, reimbursement and uptake. The approval therefore changes the commercial status of asundexian, but it does not by itself quantify future revenue.

Stock remains below its annual high

Bayer stock was trading at EUR 45.38 at Lang & Schwarz on October 26, 2026 at 3:04 p.m. CET, 3.18 percent above the Xetra close of October 23, 2026 at EUR 43.98. The price was also below the 52-week high of EUR 53.92 shown for BAYN.DE on October 26, 2026.

The further course of trading is shown by the continuously updated real-time quote of Bayer stock.